- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02194517
Impact of ELKa, the Toolset for Food Exchanges Calculation on Metabolic Control in Pediatric Diabetic Patients.
Impact of ELKa, the Toolset for Prandial Insulin Dose Calculation on Metabolic Control in Children and Adolescent With Diabetes Type 1.
ELKa system is an advanced toolset which helps performing calculation of carbohydrate (CHO) and fat/protein (FP) exchanges. It consists of ELKa software including database of various meals and nutrients and ELKaPlus digital kitchen scale transmitting weight of products in a real-time to a computer via universal serial bus (USB) port. After choosing the name of particular product from the list, the program gives precise information about the amount of CHO and FP exchanges in serving.
The aim of the study is to investigate the benefit of using ELKa toolset in comparison with standard method of CHO and FP counting on metabolic control in type 1 diabetic children.
Studieoversikt
Detaljert beskrivelse
A randomized, controlled, parallel, open-label 26-week clinical trial will be conducted in 106 pediatric patients with type 1 diabetes mellitus (DM). Patients will be randomly assigned into two groups: the group A (n=53) using ELKa system for food exchange counting and the group B (n= 53) using standard method.
The glycated hemoglobin levels will be measured in both groups at the beginning, after 3 and 6 months of observation. The group A also will be asked about the frequency of using the toolset. We will also assess secondary endpoints (mentioned below).
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Warsaw, Polen
- Medical University of Warsaw
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age under 18 y
- Confirmed DM type 1
- DM for > 1 year
- HbA1c ≤ 10%
- Computer meeting ELKa system minimum requirements
- Kitchen arrangement providing enough space for computer with ELKa system
- Written informed consent
Exclusion Criteria:
- DM other than type 1
- Duration of diabetes < 1 year
- Conventional insulin therapy
- Nutritional disorders
- Celiac disease recognized in less than 4 months before inclusion
- Preceding experience with software
- Expected 21 or more consecutive days pausing in system usage
- Any medical condition, which, in the opinion of the investigator, would interfere with the evaluation of the subject
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: control (B)
Patients performing CHO and FP exchanges calculation with standard method.
|
|
Eksperimentell: ELKa (A)
Patients counting CHO and FP exchanges with ELKa toolset.
|
ELKa should be used for every meal preparation.
After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving.
No standard calculation of exchanges need to be performed.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
HbA1c (glycated hemoglobin)
Tidsramme: 6 months
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
HbA1c (glycated hemoglobin)
Tidsramme: 3 months
|
3 months
|
|
ELKa usage frequency
Tidsramme: 3 months
|
Self-reported in questionnaire
|
3 months
|
ELKa usage frequency
Tidsramme: 6 months
|
Self-reported in questionnaire
|
6 months
|
Post- prandial glycemia
Tidsramme: 3 months
|
Mean post-prandial glycemia counted after the meal consumed between 1- 6 pm during subsequently 7- 10 days
|
3 months
|
Post- prandial glycemia
Tidsramme: 6 months
|
Mean post-prandial glycemia counted after the meal consumed between 1- 6 pm during subsequently 7- 10 days
|
6 months
|
mean diurnal glucose level
Tidsramme: 3 months
|
3 months
|
|
mean diurnal glucose level
Tidsramme: 6 months
|
6 months
|
|
Mean daily insulin dose [Insulin/kg/24h]
Tidsramme: 3 months
|
3 months
|
|
Mean daily insulin dose [Insulin/kg/24h]
Tidsramme: 6 months
|
6 months
|
|
BMI- standard deviation (BMI- sds)
Tidsramme: 3 months
|
3 months
|
|
BMI- standard deviation (BMI- sds)
Tidsramme: 6 months
|
6 months
|
|
Hypoglycemia episodes and severe hypoglycemia events
Tidsramme: 3 months
|
Hypoglycemia defined as glycemia below 70 mg/dl and, separately, glycemia below 50 mg/dl.
Self-reported.
|
3 months
|
Hypoglycemia episodes and severe hypoglycemia events
Tidsramme: 6 months
|
Hypoglycemia defined as glycemia below 70 mg/dl and, separately, glycemia below 50 mg/dl.
Self-reported.
|
6 months
|
Mean Amplitude of Glycemic Excursions (MAGE)
Tidsramme: 3 months
|
Measured in subgroup of patients with continuous glucose monitoring system (CGMS)
|
3 months
|
Mean Amplitude of Glycemic Excursions (MAGE)
Tidsramme: 6 months
|
Measured in subgroup of patients with CGMS
|
6 months
|
Glucose Area Under the Curve (AUC)
Tidsramme: 3 months
|
Measured in subgroup of patients with CGMS
|
3 months
|
Glucose Area Under the Curve (AUC)
Tidsramme: 6 months
|
Measured in subgroup of patients with CGMS
|
6 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Treatment satisfaction
Tidsramme: 6 months
|
Questionnaire regarded treatment satisfaction and wish to continuation.
|
6 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Agnieszka Szypowska, Professor, Medical University of Warsaw
- Studieleder: Agnieszka Kowalska, MD, Medical University of Warsaw
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ELKA-01
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 1 diabetes mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.FullførtDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinavhengig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | Diabetes mellitus, sprø | Diabetes mellitus... og andre forholdForente stater
-
University of California, San FranciscoJuvenile Diabetes Research FoundationFullførtType 1 diabetes mellitus | Diabetes mellitus, type I | Insulinavhengig diabetes mellitus 1 | Diabetes mellitus, insulinavhengig, 1 | IDDMForente stater, Australia
-
Capillary Biomedical, Inc.FullførtDiabetes mellitus, type 1 | Type 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, insulinavhengig, 1Australia
-
Spiden AGDCB Research AGFullførtType 1 diabetes mellitus | Type 1 diabetes mellitus med hypoglykemi | Type 1 diabetes mellitus med hyperglykemiSveits
-
Capillary Biomedical, Inc.AvsluttetType 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, type I | Diabetes mellitus, insulinavhengig, 1 | IDDMØsterrike
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute...UkjentType 1 diabetes mellitus med hyperglykemi | Type 1 diabetes mellitus med hypoglykemiPolen
-
SanofiFullførtType 1 Diabetes Mellitus-Type 2 Diabetes MellitusUngarn, Den russiske føderasjonen, Tyskland, Polen, Japan, Forente stater, Finland
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)FullførtType 1 diabetes mellitus | T1DM | T1D | Nyoppstått type 1 diabetes mellitusForente stater, Australia
-
Shanghai Changzheng HospitalRekrutteringSprø type 1 diabetes mellitusKina
-
AstraZenecaFullførtType 2 diabetes mellitus | Type 1 diabetes mellitusForente stater